We focus on innovative treatments for patients suffering from ophthalmic, neurological, and neuromuscular diseases. Our first candidate drug is in development for Retinitis Pigmentosa (RP) and in evaluation for other Retina Neurodegenerative Diseases including dry AMD, Optic Atrophy. We initially focus on rare diseases with great unmet medical need and blockbuster potential, and then will expand to other diseases. We will further evaluating them for use in serious neurological / neuromuscular diseases such as Alzheimer, Huntington and Parkinson and ALS diseases.
Our team is composed of passionate and innovative founders and experts who have solid track records in rug development and clinical research in multinational pharmaceutical companies or management experience in international technology enterprises. Their determination in bringing life-changing treatments to patients encompasses everything they do.